MAPT and Alzheimer disease: Although plasma p‐tau217, GFAP, and NfL exhibit considerable potential in the context of AD, there is a paucity of studies that concurrently examine their associations with brain Aβ/tau burdens and stages, hippocampal atrophy, and cognitive decline.